Creating targeted cell therapy for heart disease in minority patients
Official title: Development of targeted cellular therapy for atherosclerotic vascular disease in minority patients
Funded at Asclepia Technology LLC · NIH-10815000 · Data updated 2026-11-12
This study is testing a new treatment using special cells to help repair damaged blood vessels in people, especially in minority groups who are more affected by heart disease, with the goal of improving their heart health and reducing the risk of serious problems like heart attacks and strokes.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Asclepia Technology LLC NIH-funded |
| Lab location | 1 site (Sugar Land, United States) |
| Project start | June 7, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $295,892 |
| NIH project number | 1R43HL172300-01 |
| Project ID | NIH-10815000 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are minority patients suffering from atherosclerotic vascular disease, particularly those with risk factors such as diabetes, obesity, or a history of smoking.
✕Less likely to help
Patients who do not have atherosclerotic vascular disease or those who are not part of the targeted minority populations may not benefit from this research.
What this research studies
This research focuses on developing a targeted cellular therapy aimed at treating atherosclerotic vascular disease, particularly in minority populations who are disproportionately affected. The approach involves utilizing vascular stem cells to repair damaged arterial walls caused by advanced atherosclerotic plaques, which can lead to serious cardiovascular events like heart attacks and strokes. By addressing the underlying cellular dysfunction, the research aims to improve the health outcomes for patients suffering from this condition. The study will explore the effectiveness of these therapies in restoring vascular health and reducing the risk of life-threatening complications.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly improve cardiovascular health and reduce the incidence of heart attacks and strokes in vulnerable populations.
How similar studies have gone: While there have been advancements in cardiovascular therapies, this specific approach using vascular stem cells for atherosclerotic disease is relatively novel and has not been extensively tested in similar contexts.
Where this research is happening
-
Asclepia Technology LLC
Sugar Land, United States Active
Researchers
- Principal investigator: Geng, Yong Jian — Asclepia Technology LLC
- Study coordinator: Geng, Yong Jian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.